Sanofi makes $548M deal for Acambis

Sanofi Pasteur has inked a deal to buy vaccine-maker Acambis for about $548 million (£276 million), a 64 percent per-share premium. The two companies had already been working together on a couple of in-pipeline products, including dengue, West Nile virus, and Japanese encephalitis vaccines. But Acambis' most valuable product is its smallpox vaccine, for which it recently won a $425 million, 10-year contract to supply the U.S. government.

The deal is further evidence of the strength in the vaccines market, once seen as a sort of also-ran in the pharma biz. Nowadays, vaccines are becoming favored assets as they prove more profitable, thanks to scientific advances and various emerging infectious disease problems.

- check out Sanofi's release
- read the Financial Times article

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.